Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
|Articles|April 17, 2020
Helping Patients and the Public Endure the Pandemic
Author(s)Allen Frances, MD
Allen Frances, MD, delivers a powerful message for mental health professionals to help them navigate the COVID-19 pandemic.
Advertisement
Allen Frances, MD, delivers a powerful message for mental health professionals about the impact of the COVID-19 pandemic on mentally ill patients, clinicians, and the health care system. He offers solutions that may help you navigate these uncertain times.
Advertisement
Related to this article
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
2
Can Digital Memory Tests Detect Tau-Related Cognitive Change Before Alzheimer Disease?
3
FDA Shelves Fast-Track Drug Review Initiative
4
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
5